Deferiprone

1. Deferiprone: Product Overview & Specifications

Deferiprone (C₇H₉NO₂) is an oral iron-chelating agent approved by the FDA and EMA for treating transfusion-dependent iron overload. Its molecular weight is 139.15 g/mol, with a bioavailability of 60-80% and a half-life of 2-3 hours.

Key Parameters

2. Key Applications & Therapeutic Uses

Deferiprone is clinically validated for:

• Chronic iron overload in thalassemia major patients
• Myelodysplastic syndromes (MDS) with secondary iron accumulation
• Non-transfusion-dependent hemosiderosis

Its dual mechanism crosses the blood-brain barrier, making it effective for neurodegenerative iron disorders like Parkinson’s disease (off-label use).

3. Clinical Case Studies

Case 1: Pediatric Thalassemia Management

A 12-year-old β-thalassemia patient showed 40% reduction in liver iron concentration (LIC) from 12 mg/g dw to 7.2 mg/g dw after 6 months of Deferiprone monotherapy (75 mg/kg/day).

Case 2: MDS with Cardiac Involvement

65-year-old MDS patient achieved 30% improvement in cardiac T2* MRI values (from 8 ms to 10.4 ms) within 12 months, reducing arrhythmia risk.

4. Efficacy & Safety Profile Comparison

5. Verified Client Implementations

Hospital Network – Mumbai, India

Implemented Deferiprone in 150+ thalassemia patients (2022-2024):

• 82% adherence rate vs. 58% with previous therapy
• 22% lower hospitalization costs

Oncology Center – Rome, Italy

Reduced transfusion frequency by 35% in MDS cohort through combined Deferiprone-EPO protocol.

6. Request Protocol Customization

Contact our hematology specialists:

Email: info@vivalr.com
Phone: (86) 15866781826

⇨ Download our Iron Chelation Therapy Decision Tree (PDF) for clinical workflows.